

Medivir to present at the Redeye Technology & Life Science Day

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, today announces that the company will participate at the Redeye Technology & Life Science Day, tomorrow, December 3, 2024.

CEO Jens Lindberg will participate in an In Focus interview at 10.40 CET, led by Redeye analyst Richard Ramanus. The interview will focus on the recently presented data at the ESMO conference and how they strengthen the ambition to make fostrox + Lenvima® the first, approved treatment option in second-line HCC.

The presentation is live broadcasted and can be followed at the event page;

<https://www.redeye.se/events/1038747/redeye-technology-life-science-day>

The presentation will be available on Medivir's website after the meeting.

For additional information, please contact;

Magnus Christensen, CFO, Medivir AB

Telephone: +46 8 5468 3100

E-mail: magnus.christensen@medivir.com

About Medivir

Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a drug candidate designed to selectively treat cancer cells in the liver and to minimize side effects. Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list. www.medivir.com.